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Meningococcal disease remains one of the most serious
bacterial infections in both Western and developing countries.
Despite recent advances in treatment the mortality rate remains
at about 12%.1 There is a group of South Africans who are
particularly vulnerable to this disease. They are individuals
with genetically determined deficiencies of individual terminal
complement proteins, in particular of the sixth component of
complement (C6).2
The human complement system forms part of the humeral
immune system and consists of a series of proteins.3 The
interaction of antigen (such as components of bacterial outer
membranes) and antibody leads to activation of the first
component C1q, and consequent activation of part or all of the
complement cascade. This has a number of biological effects
including the formation on the membrane of the membrane
attack complex (MAC) from components C5b, C6, C7, C8 and
C9. The MAC is able to mediate lysis of some mammalian cells
such as red blood cells, as well as lysis of bacteria and certain
viruses. This action of complement has been recognised for
many years as playing a major role in defence against infection.4
In addition, MAC action is often sublytic on nucleated host
cells, and this interaction can sometimes stimulate cellular
biosynthesis and act in a pro-inflammatory manner.5 
Many other complement proteins, and products of
complement activation, also interact with the cellular immune
system and the inflammatory system. If activation is caused by
pathological processes such as ischaemia, complement can be
an important contributor to host tissue necrosis.6 The effects of
complement activation are very complex and can be
detrimental as well as beneficial.
Our patients
In the Western Cape we have been caring for patients with C6
deficiency (C6D) for a number of years.2,7 These patients are
susceptible to neisserial infections, particularly meningococcal
disease.8 However, despite complete absence of serum
bactericidal activity, patients may be no more susceptible than
normal individuals to infections not caused by encapsulated
bacteria.  
Approximately 45 individuals with C6 deficiency have been
diagnosed in the Western Cape, and a few in Gauteng. The
most common presentation is with recurrent meningococcal
infections. Subjects are likely to have suffered their first
infection after the pre-school years. Family studies have
revealed some C6D siblings of index cases who have suffered
no infections at all. 
The diagnosis is made by first determining the patient's total
haemolytic complement. Subjects with homozygous complete
C6 deficiency lack all complement haemolytic function. Low
haemolytic activity can be found in other diseases such as
systemic lupus erythematosus and C1 esterase inhibitor
deficiency, and it is therefore necessary to distinguish absent
complement activity from low activity. Also, genetic deficiency
of any of the terminal complement proteins presents in the
same manner, so the specific diagnosis of C6 deficiency can
only be made with an additional specific C6 haemolytic or
antigenic assay. 
Many individuals with C6 deficiency may not be diagnosed
because individuals with only one episode of meningococcal
infection are seldom investigated. However, in our patients the
morbidity costs of repeated infections are high so steps need to
be taken to protect these vulnerable individuals from further
infections. The most common problems we have seen are
deafness and mental retardation. It has been suggested that
individuals with complement deficiency suffer milder
meningococcal disease than normal individuals.4 However,
there is no convincing evidence that primary meningococcal
infection is milder in complement-deficient individuals.
What can be done
The problem is how to protect these individuals. The first step
is education and counselling so that patients or their parents
know the problem, and know that it is essential to obtain rapid
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treatment should the signs and symptoms of meningococcal
disease occur. 
Patients lack serum bactericidal activity, and because
antibodies require complement activity to mediate
bacteriolysis, vaccination at best can only provide partial
protection. Nevertheless, vaccination can enhance
opsonophagocytosis, and vaccination with the tetravalent
polysaccharide capsule vaccines A, C, Y and W135 is
recommended for terminal complement-deficient individuals
in Europe and other Western countries where meningococcal
group B infections are rare.9 However, group B was found to be
the most common meningococcal strain isolated from Cape C6-
deficient patients,10 and it remains the most prevalent strain
isolated in this country.11 Until a satisfactory group B vaccine is
available vaccination can only provide very partial protection
and our patients have not been vaccinated. 
Antibiotic prophylaxis, usually in the form of monthly
bicillin injections, was used to protect the more vulnerable of
the Cape patients. That study7 was carried out over a 3-year
period from 1984 to 1986 and showed that antibiotics did
lessen the risk of recurrent infections. We are at present
carrying out a further study to investigate the effectiveness of
antibiotic prophylaxis over a much longer timespan.
Long-term implications
What are the long-term implications of terminal complement
component deficiency? The Western Cape cohort of C6-
deficient subjects is large compared with cases reported from
elsewhere, and we first examined many of these patients
approximately 18 years ago. The cohort therefore provides an
opportunity to investigate the long-term consequences of
deficiency. However, the total number of patients is not large
and although we have seen C6-deficient patients with
tuberculosis and other diseases we cannot yet say whether C6-
deficiency is a predisposing factor. An association between
auto-immune disease and terminal component deficiency is
still speculative.12,13
Interactions between components of the complement system
and the inflammatory system are known, and participation of
complement in disease processes is now being recognised.6,14
Some possible unwanted manifestations of complement
activation only occur in diseases associated with ageing, such
as atheroma formation, necrosis following myocardial
infarction, arthritis, and central nervous system diseases such
as multiple sclerosis. It is therefore possible that there are
beneficial effects of lacking terminal complement component
activity.
Genetic defects responsible for C6 deficiency in the Cape
were described in 1998.15 Three defects were found among the
Cape patients. One defect (879delG) has only been found in the
Cape and the Netherlands, and the other (1195delC) has been
observed in individuals of West African origin.16 The third
defect (1936delG) has also been observed in people of West
African origin but only one instance of this gene was observed
in the Cape. 
Deficiency of C6 is an interesting genetic deficiency that may
help us understand the role of complement in a number of
disease processes. However, it is also a serious disease as it
predisposes to life-threatening infections. These patients need
to be diagnosed and then given appropriate care to try and
prevent further recurrences of meningococcal infection.
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